130 related articles for article (PubMed ID: 19337828)
21. Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway.
Thoennissen NH; O'Kelly J; Lu D; Iwanski GB; La DT; Abbassi S; Leiter A; Karlan B; Mehta R; Koeffler HP
Oncogene; 2010 Jan; 29(2):285-96. PubMed ID: 19855437
[TBL] [Abstract][Full Text] [Related]
22. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines.
Luk F; Yu Y; Walsh WR; Yang JL
Cancer Invest; 2011 Oct; 29(8):521-32. PubMed ID: 21843050
[TBL] [Abstract][Full Text] [Related]
23. Treatment of breast cancer cells by IGF1R tyrosine kinase inhibitor combined with conventional systemic drugs.
Hartog H; Van Der Graaf WT; Boezen HM; Wesseling J
Anticancer Res; 2012 Apr; 32(4):1309-18. PubMed ID: 22493363
[TBL] [Abstract][Full Text] [Related]
24. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH
Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487
[TBL] [Abstract][Full Text] [Related]
25. Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Jansen GH; Franke HR; Wolbers F; Brinkhuis M; Vermes I
Climacteric; 2008 Aug; 11(4):315-21. PubMed ID: 18645697
[TBL] [Abstract][Full Text] [Related]
26. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib.
Chakraborty AK; Zerillo C; DiGiovanna MP
Breast Cancer Res Treat; 2015 Aug; 152(3):533-44. PubMed ID: 26195122
[TBL] [Abstract][Full Text] [Related]
28. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
McDermott MSJ; Canonici A; Ivers L; Browne BC; Madden SF; O'Brien NA; Crown J; O'Donovan N
Int J Oncol; 2017 Jun; 50(6):2221-2228. PubMed ID: 28498399
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.
Koay DC; Zerillo C; Narayan M; Harris LN; DiGiovanna MP
Breast Cancer Res; 2010; 12(4):R62. PubMed ID: 20696059
[TBL] [Abstract][Full Text] [Related]
30. Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.
Chakraborty A; Hatzis C; DiGiovanna MP
Breast Cancer Res Treat; 2017 May; 163(1):37-50. PubMed ID: 28236033
[TBL] [Abstract][Full Text] [Related]
31. Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.
Jiang D; Huang Y; Han N; Xu M; Xu L; Zhou L; Wang S; Fan W
Cancer Lett; 2014 May; 346(2):292-9. PubMed ID: 24462822
[TBL] [Abstract][Full Text] [Related]
32. Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma.
Maillard S; Ameller T; Gauduchon J; Gougelet A; Gouilleux F; Legrand P; Marsaud V; Fattal E; Sola B; Renoir JM
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):111-21. PubMed ID: 15862956
[TBL] [Abstract][Full Text] [Related]
33. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
Mai Z; Blackburn GL; Zhou JR
Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
[TBL] [Abstract][Full Text] [Related]
34. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma.
Alvaro D; Barbaro B; Franchitto A; Onori P; Glaser SS; Alpini G; Francis H; Marucci L; Sterpetti P; Ginanni-Corradini S; Onetti Muda A; Dostal DE; De Santis A; Attili AF; Benedetti A; Gaudio E
Am J Pathol; 2006 Sep; 169(3):877-88. PubMed ID: 16936263
[TBL] [Abstract][Full Text] [Related]
35. NJK14013, a novel synthetic estrogen receptor-α agonist, exhibits estrogen receptor-independent, tumor cell-specific cytotoxicity.
Kim HI; Kim T; Kim JE; Lee J; Heo J; Lee NR; Kim NJ; Inn KS
Int J Oncol; 2015 Jul; 47(1):280-6. PubMed ID: 25964080
[TBL] [Abstract][Full Text] [Related]
36. IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer.
Bruchim I; Sarfstein R; Reiss A; Flescher E; Werner H
Cancer Lett; 2014 Oct; 352(2):214-9. PubMed ID: 24997432
[TBL] [Abstract][Full Text] [Related]
37. Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells.
Gaben AM; Sabbah M; Redeuilh G; Bedin M; Mester J
BMC Cancer; 2012 Jul; 12():291. PubMed ID: 22799881
[TBL] [Abstract][Full Text] [Related]
38. A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer.
Wester L; Venneker S; Hazenoot M; Pont C; Koedoot E; Timmermans AM; Martens JWM; Jansen MPHM; Kockx CEM; van IJcken WFJ; Meerman JHN; Zhang Y; van de Water B
Biochem Pharmacol; 2022 Oct; 204():115233. PubMed ID: 36041543
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
Zeng X; Zhang H; Oh A; Zhang Y; Yee D
Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
[TBL] [Abstract][Full Text] [Related]
40. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.
Zeng X; Sachdev D; Zhang H; Gaillard-Kelly M; Yee D
Clin Cancer Res; 2009 Apr; 15(8):2840-9. PubMed ID: 19351773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
